Skip to main content

Enrolling Polymyalgia Rheumatica Studies


Sponsor: Novartis

Protocol Number: CAIN457C2231

The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who have recently relapsed.

Detailed Information: Here

To learn more or see if you qualify: Click Here